『The Lancet in conversation with』のカバーアート

The Lancet in conversation with

The Lancet in conversation with

著者: The Lancet Group
無料で聴く

Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.© 2026 The Lancet Group 衛生・健康的な生活 身体的病い・疾患
エピソード
  • What are cardiometabolic long-term conditions?
    2026/07/10

    What are cardiometabolic long-term conditions? To mark the publication of a new Lancet Series, editors Niall Boyce and Flávia Geraldes talk to Professor Kamlesh Khunti of the University of Leicester. They learn about a new way of conceptualising common medical conditions that has the potential to radically transform both health services and patient outcomes.

    Click here to read the full series:

    https://www.thelancet.com/series-do/lancet-series-cardiometabolic-multiple-long-term-conditions

    続きを読む 一部表示
    19 分
  • Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology
    2026/05/31

    In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field.

    The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era.

    Visit the lancet.com to discover more

    続きを読む 一部表示
    33 分
  • Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement
    2026/05/19

    Do we need to rethink our response to conflict and forced displacement? A new Lancet Commission radically rethinks policy, funding, and practical approaches to humanitarian crises. Chair Professor Paul Spiegel joins Niall Boyce from the Lancet to discuss the aims and recommendations of this Commission on one of the most pressing health issues of the 21st century.

    Click here to visit the commission page and read the full article:

    www.thelancet.com/commissions-do/conflict-forced-displacement

    続きを読む 一部表示
    32 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません